靶向药物时代局部晚期甲状腺癌的新辅助治疗
收稿日期: 2021-09-27
网络出版日期: 2022-07-27
基金资助
国家自然科学基金(82072951);国家自然科学基金青年项目(81902721);上海抗癌协会上海市科委西医引导项目(19411966600);上海市抗癌协会翱翔计划项目(SACA-AX106);上海申康医院发展中心项目(SHDC2020CR6003);上海市青年科技英才扬帆计划(19YF1409300)
New adjuvant treatment of locally advanced thyroid carcinoma in era of targeted therapy
黄乃思, 陈嘉莹, 嵇庆海, 王宇 . 靶向药物时代局部晚期甲状腺癌的新辅助治疗[J]. 外科理论与实践, 2021 , 26(06) : 493 -496 . DOI: 10.16139/j.1007-9610.2021.06.006
| [1] | 田文, 樊友本, 房居高, 等. 局部晚期甲状腺癌手术治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(4):369-376. |
| [2] | Wang LY, Nixon IJ, Patel SG, et al. Operative management of locally advanced, differentiated thyroid cancer[J]. Surgery, 2016, 160(3):738-746. |
| [3] | Chen W, Sun K, Zheng H, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1):1-12. |
| [4] | Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases[J]. J Clin Endocrinol Metab, 1999, 84(11):4043-4049. |
| [5] | Beasley NJ, Walfish PG, Witterick I, et al. Cause of death in patients with well-differentiated thyroid carcinoma[J]. Laryngoscope, 2001, 111(6):989-991. |
| [6] | Hartl DM, Zago S, Leboulleux S, et al. Resection margins and prognosis in locally invasive thyroid cancer[J]. Head Neck, 2014, 36(7):1034-1038. |
| [7] | Rubens RD, Sexton S, Tong D, et al. Combined chemotherapy and radiotherapy for locally advanced breast cancer[J]. Eur J Cancer, 1980, 16(3):351-356. |
| [8] | Tsuboi M, Takizawa H, Aoyama M, et al. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report[J]. Int J Surg Case Rep, 2017, 41:89-92. |
| [9] | Iwasaki H, Toda S, Ito H, et al. A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy[J]. Case Rep Endocrinol, 2020, 2020:6438352. |
| [10] | Stewart KE, Strachan MWJ, Srinivasan D, et al. Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report[J]. Eur Thyroid J, 2019, 8(2):102-107. |
| [11] | Danilovic DLS, Castro G Jr, Roitberg FSR, et al. Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer[J]. Arch Endocrinol Metab, 2018, 62(3):370-375. |
| [12] | Nava CF, Scheffel RS, Cristo AP, et al. Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma[J]. Front Endocrinol (Lausanne), 2019, 10:712. |
| [13] | Cleary JM, Sadow PM, Randolph GW, et al. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib[J]. J Clin Oncol, 2010, 28(23):e390-e392. |
| [14] | Golingan H, Hunis B, Golding AC, et al. Neoadjuvant Lenvatinib in advanced unresectable medullary thyroid carcinoma: a case report[J]. AACE Clin Case Rep, 2019, 6(2):e73-e78. |
| [15] | Jozaghi Y, Zafereo M, Williams MD, et al. Neoadjuvant selpercatinib for advanced medullary thyroid cancer[J]. Head Neck, 2021, 43(1):E7-E12. |
| [16] | Cabanillas ME, Ferrarotto R, Garden AS, et al. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma[J]. Thyroid, 2018, 28(7):945-951. |
| [17] | Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma[J]. Thyroid, 2019, 29(8):1036-1043. |
| [18] | Huang NS, Wei WJ, Xiang J, et al. The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: a single-arm phase Ⅱclinical trial[J]. Thyroid, 2021[online ahead of print]. |
| [19] | Li D, Chi Y, Chen X, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase ⅡB trial[J]. Clin Cancer Res, 2021, 27(13):3567-3575. |
| [20] | Chi Y, Gao M, Zhang Y, et al. LBA 88 anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phaseⅡ trial[J]. Ann Oncol, 2020, 31(S4):S1215. |
/
| 〈 |
|
〉 |
